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5ABSTRACT
Background: Heart failure (HF) is a major health problem worldwide with an estimated 
prevalence of about 1-2% in the Western world. The temporal trend for prevalence of HF 
has never been investigated in a nationwide population. In patients with HF diuretic treat-
ment is recommended for relief of congestive symptoms. Over 80% of all patients with 
HF are estimated to be treated with diuretics. However, information about the temporal 
trend for diuretic treatment in a nationwide population is lacking and the prognostic effect 
of diuretic treatment in patients with HF has never been studied in a randomized clinical 
trial. Diuretics have been associated with increased mortality in selected populations with 
HF but the association of diuretics with mortality in unselected Western world patients 
discharged from a hospitalization for HF or in unselected outpatients with HF has not 
been studied.
Aim: The aims of this thesis was to study trends for prevalence of patients hospitalized 
with HF 1990-2007, trends for diuretic treatment in patients hospitalized for HF 2004-
2011, the association of diuretic treatment at hospital discharge from a hospitalization for 
HF with short- and long-term mortality, and to evaluate diuretic treatment as a prognostic 
predictor for long-term mortality in outpatients with HF.
Methods and results: Data from several different Swedish registries were linked in these 
studies. Patients hospitalized with a primary or secondary diagnosis of HF aged 19-99 
years 1990-2007 were included in Paper I. An increase in age-adjusted prevalence of HF 
until 1995 and a decrease from 2002 to 2007 was observed. Prevalence of HF in people 
aged less than 55 years increased throughout the observational period. In absolute num-
bers, patients with HF older than 85 years increased by 77% from 1990 to 2007 (Paper 
I). Patients with a fi rst-time hospitalization for HF that survived for 18 months or more 
after discharge were included in Paper II. Post-discharge diuretic treatment and doses 
decreased 2005-2014 and coincided with increased neuro-hormonal antagonist treatment 
rates (Paper II). Patients recorded in the Swedish HF registry 2004-2011 with known 
diuretic treatment status were included in Paper III and IV. Diuretic treatment at hospital 
discharge had a neutral association with short-term mortality but was associated with in-
creased long-term mortality (Paper III). Diuretic treatment in unselected outpatients with 
HF was independently associated with increased long-term mortality but did not improve 
a previously known model for prediction of 3-year mortality (Paper IV).
Conclusions: The prevalence of HF decreased 2002-2007 but may increase in the future 
due to increased prevalence in young persons and the demographic transition. If the ob-
served trend for decreased post-discharge diuretic treatment rates and doses in patients 
with HF 2005-2014 was related to the observed coinciding increase of treatment with 
neuro-hormonal antagonists  was not answered by this study. If the observed associations 
of diuretic treatment with increased long-term mortality in real-life patients with HF was 
related to a direct prognostic effect of diuretic treatment or to diuretic treatment as a 
marker for HF disease severity remains unknown. 
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NT-proBNP  N-terminal prohormone of brain natriuretic peptide
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PRA   plasma renin activity
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RAAS   renin angiotensin aldosterone system
RAS   renin angiotensin system
RCT   randomized clinical trial
ROC   receiver operating characteristic
SPDR   The Swedish Prescribed Drug Register
SwedeHF  The Swedish Heart Failure Registry
WHO   World Health Organisation
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INTRODUCTION
The defi nition of heart failure
Several defi nitions of heart failure (HF) have been suggested. One of the most fre-
quently used was presented by Eugen Braunwald in 1967, ‘a clinical syndrome char-
acterized by well-known symptoms and physical signs. . . . [It is] the pathological 
state in which an abnormality of myocardial function is responsible for the failure of 
the heart to pump blood at a rate commensurate with the requirements of the metabo-
lizing tissues during ordinary activity’ (1). A developed and modernized version was 
suggested by Milton Packer in 1988, ‘HF represents a clinical syndrome characterized 
by abnormalities of left ventricular function and neuro-hormonal regulation which are 
accompanied by effort intolerance, fl uid retention and reduced longevity’.
Causes and comorbidities in patients with heart failure
There are many different causes of HF, e.g. ischaemic heart disease, hypertension, 
diabetes mellitus, infectious diseases, valvular diseases, tachyarrhythmia, abuse of al-
cohol or drugs, chemotherapy, and ‘idiopathic’ dilated cardiomyopathy (where about 
25% have a genetic basis) (2). The causes of HF vary in importance in different parts 
of the world. In the individual patient with HF, the exact cause or causes of HF, and 
the distinction between cause and comorbidity, may be diffi cult to establish. Examples 
of frequently occurring comorbidities in patients with HF are ischemic heart disease, 
hypertension, diabetes mellitus, atrial fi brillation and chronic kidney dysfunction (3). 
The pathophysiology of decompensated heart failure
The pulmonary and peripheral oedema seen in HF is the result of multiple physiologic 
disturbances. Decreased cardiac output leads to a relative renal hypoperfusion that 
stimulates neuro-hormonal activation of the renin angiotensin aldosterone axis. This 
activation results in increased activity of the renal sympathetic nerve, increased activi-
ty of the renin angiotensin aldosterone system, and increased secretion of vasopressin. 
Increased secretion of vasopressin contributes to venous congestion through aqua-
porin mediated retention of water (4). Retention of free water and sodium results in 
increased volume and pressure in capacitance vessels. Hydrostatic pressure elevation 
leads to fl uid extravasation into peripheral tissues and lungs. In acute decompensated 
HF (ADHF), the heart is not able to effectively increase stroke volume when exposed 
to elevated fi lling pressures. Acute elevation of left ventricular preload (end-diastolic) 
pressure directly leads to elevated left atrial pressure, elevated pulmonary capillary 
wedge pressure (PCWP) and eventually pulmonary oedema (5). Fluid retention and 
congestion are estimated to be present in 95% of patients with acute HF (AHF) (2). 
Clinical signs and symptoms of congestion are the most common fi ndings in patients 
at admission to hospital for ADHF (6). However, sub-clinical signs of congestion 
have been observed in patients with HF both before and after an episode of clinical de-
compensation. Increased intrathoracic fl uid documented by intrathoracic impedance 
monitoring has been observed as early as 18 days before hospitalization for HF (7). 
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Increased weight (8) and elevated PCWP (9) have been observed several days before 
clinical pulmonary oedema and hospitalization for HF. Residual sub-clinical conges-
tion documented by pulmonary ultrasound has been observed in patients at discharge 
from a HF hospitalization (10) and clinically unrecognized hypervolemia has been 
observed in non-oedematous patients with chronic HF (CHF) (11). 
In addition, congestion has been found to be the most important hemodynamic factor 
driving the worsening renal function (WRF) observed in patients with HF (12). HF 
and WRF constitute the cardio-renal syndrome. The cardio-renal syndrome was de-
fi ned by the National Heart, Lung, and Blood Institute in 2004 as a condition in which 
therapy to relieve congestive symptoms of HF is limited by a decline in renal function 
as manifested by a reduction in glomerular fi ltration rate. 
The diagnosis of heart failure
Diagnoses in medical records are registered with classifi cation codes. The World 
Health Organisation (WHO) Nomenclature Regulations, adopted in 1967, stipulated 
that Member States should use the most current International Classifi cation of Dis-
eases (ICD) revision for mortality and morbidity statistics. Since 1967, the ICD has 
been continuously revised and published in a s eries of editions to refl ect advances in 
health and medical science over time. The current version, ICD-10, was endorsed in 
May 1990. 
Signs and symptoms seen in HF may resemble signs and symptoms seen in other 
diseases. These signs and symptoms can be hard to identify and distinguish in obese 
persons, in the elderly, and in patients with chronic pulmonary disease. Several sets 
of diagnostic criteria for HF, based on a combination of clinical signs, symptoms, and 
examination fi ndings have been proposed. In the era when non-invasive techniques 
for assessing systolic and diastolic dysfunction were not yet widely available, the 
Framingham (13), Duke (14), Boston (15) and Gothenburg (16) criteria were pro-
posed in 1971, 1977, 1985, and 1987, respectively. Of these, the Boston criteria have 
the highest combined sensitivity (50%) and specifi city (78%) for HF (17, 18). The 
European Society of Cardiology (ESC) proposed their fi rst diagnostic criteria for HF 
in 1995 (19). Since then the ESC criteria for HF have been gradually updated. The 
latest algorithm, based on clinical fi ndings, measurement of N-terminal prohormone 
of brain natriuretic peptide (NT-proBNP), and results from echocardiographic exami-
nation was presented in 2016 (2). 
Classifi cation of heart failure related to time course
HF may be subdivided into AHF or CHF. AHF can be either “new-onset” HF or de-
compensated CHF. Patients who have had HF for some time are said to have CHF 
(2). The term ‘hospitalization for HF’ (HHF) has been proposed for patients with HF 
considered in need of hospitalization (20). HHF comprises patients with: 1) worsen-
ing CHF (∼80%); 2) de novo HF (15%); and 3) advanced or end-stage HF (5%). AHF, 
CHF and HHF are stages of the HF syndrome. There are no separate classifi cation 
codes that differentiate between AHF, CHF and HHF in the ICD coding system.
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Classifi cation of heart failure related to ejection fraction
The present main terminology used to further categorize HF is based on the measure-
ment of left ventricular ejection fraction (EF). Mathematically, EF is the stroke vol-
ume (the end-diastolic volume minus the end-systolic volume) divided by the end-di-
astolic volume. HF comprises a wide range of patients, from those with normal LVEF 
(≥50%), described as HF with preserved EF (HFpEF), to those with reduced LVEF 
(<40%), described as HF with reduced EF (HFrEF), in current guidelines (2, 21). Dif-
ferences between HFrEF and HFpEF have been observed on both macroscopic and 
cellular levels (22). Compared to patients with HFrEF, a larger proportion of patients 
with HFpEF are older, women and with a history of hypertension or atrial fi brilla-
tion, while a history of myocardial infarction is less common (23, 24). A majority of 
patients with HFrEF are estimated to die from cardiovascular causes, e.g. progressive 
HF, arrhythmias and ischaemic events whereas a majority of patients with HFpEF are 
estimated to die from non-cardiovascular causes (25). However, diastolic dysfunction 
may be diffi cult to assess and the proportion of patients with HF that have been classi-
fi ed with preserved EF have ranged from 22% to 73% in different studies (2). 
Patients with EF in the range of  >40–49% represent a ‘grey area’, or ‘mid-range’, 
defi ned as HF with mid-range EF (HFmrEF) in the latest update of ESC guidelines 
(2) and as ‘HFpEF, borderline’, in the latest update of the American College of Car-
diology Foundation/American Heart Association (ACCF/AHA) guidelines (21). EF 
in patients with HFrEF may improve with time, usually as an effect of treatment. The 
term ‘HFpEF, improved’, has been suggested in the latest ACCF/AHA guidelines for 
patients with a current EF>40% and a previous EF<40%. The phenotype of HFmrEF 
has been found to resemble HFrEF more than HFpEF (24). Long-term mortality rates 
have been reported to be somewhat higher in HFrEF than in HFpEF (26). A recent 
analysis from the European HF registry has reported highest one-year mortality rates 
in HFrEF, intermediate in HFmrEF and lowest in HFpEF (24). There are no separate 
classifi cation codes that differentiate between HFrEF, HFmrEF and HFpEF in the ICD 
coding system. 
Classifi cation of heart failure related to symptomatology
The terminology most frequently used to describe symptomatic severity in patients 
with HF is the New York Heart Association (NYHA) classifi cation that was intro-
duced in 1964. Patients in NYHA class I, II, III, and IV are said to have no, mild, 
moderate or severe symptoms, respectively. NYHA classifi cation is dynamic and may 
change with time and clinical course. 
Treatment in acute heart failure 
The fi rst-line recommended treatment in international guidelines for patients with 
ADHF is diuretics (2, 21). If the diuretic response is inadequate despite a combination 
of different diuretics, ultrafi ltration (27) for congestive relief may be considered. In 
patients with AHF and respiratory distress, non-invasive positive pressure ventilation 
should be considered. Furthermore, intravenous vasodilators should be considered as 
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the initial treatment in hypertensive AHF and, if symptomatic hypotension is absent, 
as an adjuvant to diuretic therapy for relief of dyspnoea. In patients with AHF and 
inadequate peripheral perfusion fl uid challenge, inotropes and mechanical circulatory 
support may be considered. 
Treatment with tolvaptan, a vasopressin V2 receptor antagonist (28), rolofylline, an 
adenosine receptor blocker (29), nesiritide, a synthetic natriuretic peptide (30), ular-
itide, a vasodilator (31), and serelaxin, recombinant human relaxin-2, (https://www.
escardio.org/The-ESC/Press-Offi ce/Press-releases/serelaxin-fails-to-meet-primary-
endpoints-in-phase-3-relax-ahf-2-trial) in patients with AHF has been evaluated in 
large randomize clinical trials (RCTs) without any signs of prognostic benefi ts (30). 
Results from studies on inotropes have led to debate and concerns that they may in-
crease mortality in patients with AHF (32). 
Neuro-hormonal blocking treatment in chronic HFrEF 
Treatment in chronic HFreF with prognostic benefi ts proven in RCTs is available. 
The era of neuro-hormonal blocking treatment in chronic HFrEF is modern and began 
in the 1980s when it was established that inhibition of the renin angiotensin system 
(RAS) with the angiotensin-converting–enzyme (ACE) inhibitor enalapril reduced 
overall mortality in HF (33, 34). In addition, it was shown that enalapril was superior 
to vasodilating treatment with the combination of hydralazine and isosorbide dinitrate 
(35). The 1990s was a successful decade when new treatments for chronic HFrEF 
with prognostic benefi ts were discovered. It was shown that the benefi ts of enalapril 
in reducing hospitalizations for HF also applied to asymptomatic patients (36). 
The use of beta-blocker therapy, nowadays considered as a cornerstone of HF treat-
ment, once was contraindicated in HF because of the negative inotropic and chrono-
tropic effects that were thought to affect patients with systolic dysfunction in a nega-
tive way. However, evidence of a mortality benefi t emerged for three beta-blockers, 
bisoprolol (37), carvedilol (38), and sustained-release metoprolol (39). Spironolac-
tone, a mineralocorticoid-receptor antagonist (MRA), was proven to reduce mortal-
ity in patients with severe symptoms already receiving an ACE-inhibitor and a loop 
diuretic but where only 10% of the included patients were treated with a beta-blocker 
(40). Treatment with angiotensin receptor blocker (ARB) therapy for HF was intro-
duced in the beginning of the 21st century (41), but because treatment with ARBs is 
not superior to treatment with ACE inhibitors, ARBs have generally been reserved 
for patients who cannot tolerate ACE inhibitors because of cough or angiooedema. In 
2011, it was demonstrated that treatment with the MRA eplerenone decreased mortal-
ity in patients with mild symptoms (42). In 2014, ARB and neprilysin inhibition with 
a combination of sacubitril and valsartan was shown to reduce cardiovascular and all-
cause mortality on top of standard of care, as compared to enalapril (43). 
Other treatment with prognostic benefi t in chronic HFrEF
In the 1980s, vasodilating treatment with hydralazine plus isosorbide dinitrate, as 
compared to either placebo or prazosin, was shown to reduce mortality (44). In 1997, 
the it was demonstrated that treatment with digoxin when compared to placebo did 
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not reduce overall mortality, but reduced the rate of hospitalization, both overall and 
for worsening heart failure in patients with left ventricular systolic dysfunction (45). 
However, the role of digoxin in the contemporary treatment of HF has been debat-
ed. In the beginning of the 21st century it was shown that cardiac resynchronization 
therapy (46) and implantable cardioverter-defi brillators (47) decreased mortality in 
selected patients with HFrEF. In addition, cardiac resynchronization therapy has been 
proven to reduce the risk for hospitalization for HF in selected patients with HFrEF 
and mild symptoms (48). In 2010, it was shown that treatment with the sinus node in-
hibitor ivabradine reduced the composite endpoint of cardiovascular death or hospital 
admission for worsening heart failure in selected patients with HFrEF (49). 
Treatment in chronic HFpEF
Guidelines recommend symptomatic treatment in patients with HFpEF. Treatment 
with beta-blocker (50), ARB (51) and MRA (52) in patients with HFpEF have been 
evaluated in large randomized clinical trials but without any signs of prognostic ben-
efi ts. 
Salt and water reduction in heart failure
The latest ESC recommendations for self-care management of HF consider the evi-
dence for the optimal fl uid management in the patient with HF limited (53). However, 
it is recommended that salt and water reduction may be considered in patients with 
severe symptoms. 
The history of diuretic treatment in heart failure
In the 18th century it was observed that the diuretic action of digitalis was increased 
when digitalis was combined with calomel, a mercury chloride mineral. Almost a hun-
dred year later the diuretic effect of calomel alone was shown when the administration 
of repeated small doses of calomel per os resulted in diuresis in patients with oedema 
(54). The majority of observers at that time favoured the view that calomel acted di-
rectly on the kidney.  However, warnings were expressed that treatment with calomel 
was associated with renal damage (55). Novasurol, an organic compound containing 
mercury, was introduced as an anti-syphilitic drug in the beginning of the 20th cen-
tury. The fi rst studies of Novasurol as a diuretic (56) and for the relief of oedema in 
patients with HF (57) were performed soon thereafter. However, mercurial diuretics 
were diffi cult to use and found to have toxic effects. In 1937, the diuretic effect of 
sulphonamides was investigated and one year later oral therapy with sulphonamides 
became available (58). In 1953, Diamox, a carbonic hydrase inhibitor, was introduced 
as an oral diuretic in patients with HF (59). A few years later, thiazides and thiazide-
like diuretics were introduced (60) and observed to reduce oedema in patients with HF 
(61). In the 1960s, furosemide, a loop diuretic, was synthesized. The diuretic effect 
of furosemide was found to be superior to thiazides in patients with oedema and even 
more effective in patients with oedema due to heart disease (62). Since then, loop 
diuretics has been the fi rst line treatment for congestive relief in patients with HF. 
Currently, the loop diuretics furosemide, bumetanide, and torasemide are available 
for prescription. It has been shown that torasemide has a better decongestive effect 
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than furosemide  and there have been indications that torasemide also has prognostic 
advantages when compared to furosemide (63). Nevertheless, furosemide is still the 
most frequently used loop diuretic in real life clinical practice. Diuretic treatment is 
recommended in international guidelines for relief of congestive symptoms in patients 
with HF, both in HFrEF and HFpEF. In addition, dose reduction or discontinuation, if 
clinically feasible, is recommended (2, 21). 
Year  
1799 Increased diuretic action of digitalis when given in combination with calomel 
(mercury) was observed 
1886 Diuretic effects of calomel (mercury) alone was observed 
1920 Diuretic effects of Novasurol (mercury) was observed 
1925 Novasurol (mercury) was used for relief of oedema in HF 
1937 Diuretic effects of sulphonamides was observed 
1938 The first oral sulphonamide was introduced 
1953 Carbonic anhydrase inhibitors were introduced as oral diuretics in HF 
1958 Thiazides and thiazide-like diuretics were introduced 
1960s The loop diuretic furosemide was synthesized and introduced for treatment of oedema 
in HF 
Pharmacodynamics of loop diuretic treatment
Loop diuretics inhibit chloride resorption in the ascending limb of Henle’s loop in 
the kidney. This results in increased secretion of chloride coinciding with increased 
secretion of sodium, calcium, magnesium, and potassium. The resulting diuresis is ac-
companied by a weak reduction in blood pressure. Due to variations in bioavailability 
after oral administration of furosemide, intravenous administration of furosemide is 
preferred in patients with ADHF. The threshold dose for obtaining diuretic effect after 
administration of furosemide is higher in patients with impaired renal function when 
compared to persons with normal renal function (64) and the ceiling dose is lower in 
patients with HF when compared to persons with chronic kidney disease (65). The 
diuretic effect of furosemide begins 10-30 minutes after intravenous administration 
and 1-1.5 hours after oral administration. In addition, loop diuretics induce synthesis 
of prostaglandins, resulting in renal and peripheral vascular smooth muscle relax-
ation and venous dilatation. Decrease in the dose-response diuretic effect for the given 
dose of loop diuretics over time is called diuretic resistance (66). Diuretic resistance 
is thought to be related to increased reabsorption of sodium and water in the distal 
tubules. It can to some extent be counteracted if loop diuretics are combined with 
thiazides.
Effects of diuretic treatment in patients with heart failure
In a study of patients with severe HF, it was shown that in the fi rst 20 minutes after 
intravenous administration a fall in stroke volume index and increases in left ventricu-
Table 1. The history of diuretic treatment
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lar fi lling pressure, heart rate, mean arterial pressure, systemic vascular resistance, 
plasma renin activity, plasma norepinephrine level, and plasma arginine vasopressin 
level occured (67). Later effects in that study were diuresis, reduction of the intravas-
cular volume, decreased central venous pressure, decreased right and left heart fi lling 
pressures, and decreased pulmonary vascular pressures. A recent observational study 
showed that early when compared to late administration of furosemide after admis-
sion to hospital was associated with decreased mortality in patients with ADHF (68). 
When diuretic bolus doses were compared to continuous infusion and high doses of 
diuretics were compared to low doses in the randomized DOSE trial no differences 
between these strategies were observed in the primary endpoints of patients’ global 
assessment of symptoms and  changes in renal function (6). 
Despite the reported high diuretic treatment rates in patients hospitalized for HF (69) 
many patients are discharged from a hospitalization for HF with residual congestion 
(10, 70). Residual clinical congestion at discharge from a hospitalization for HF has 
been associated with an increase in the composite endpoint of 60-day mortality, hospi-
talization and emergency department visits (70). Residual congestion measured with 
pulmonary ultrasound at hospital discharge has been associated with an increase in 
the composite endpoint of 3-month all-cause death or HF hospitalization (10). In addi-
tion, higher BNP when compared to lower BNP at discharge from a hospitalization for 
HF has been associated with increased long-term mortality (71). Diuretic treatment 
when compared to no diuretic treatment at hospital discharge has been associated 
with increased long-term mortality in a study from the Japanese HF registry (72). 
However, differences in comorbidities and prognosis between Japanese and Western 
world patients with HF have been observed, why generalization may be diffi cult to 
make (73). 
Clinical side effects e.g. fatigue, decreased exercise capacity, and hypotension may 
occur in patients with CHF treated with diuretics (74). In addition, diuretic treatment 
has been associated with increased activity of the RAS system (75), WRF (76), hy-
pokalaemia (77), and hypomagnesaemia (78) in patients with CHF. These conditions 
have directly, or indirectly, been associated with increased mortality in patients with 
CHF. Diuretic treatment has been associated with increased long-term mortality in 
selected outpatients with HF in a secondary analysis from the Digitalis Investigation 
group (DIG) study (79). 
Temporal trends for treatment in patients with chronic heart failure
Trends for increased beta-blocker, RAS inhibitor and MRA treatmnet rates have been 
observed  in selected cohorts with CHF (80-85) coinciding in time with the gradual 
introduction of these drugs in guideline recommendations. Contemporary treatment 
patterns for beta-blockers, RAS inhibitors and MRAs in patients with HF have been 
considered in adherence to guideline recommendations (69). In contrast, adherence to 
guideline recommendations on device treatment has been considered low, at least in 
Sweden (85). However, beta-blockers and RAS inhibitors may still be underused  in 
women when compared to men and in older when compared to younger persons (86, 
87). 
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In theory, successful treatment with neuro-hormonal antagonists may decrease the 
degree of fl uid retention (88) and, consequently, decrease the need for diuretic treat-
ment in patients with CHF. Nevertheless, diuretic treatment rates observed in selected 
cohorts with CHF have decreased only slightly last decades (80-85). 
Observational research
In observational studies, results are obtained either retrospectively or prospectively 
from a population that is not under the control of the investigator. Incidence is a mea-
sure of the probability of occurrence of a given medical condition in a population 
within a specifi ed period of time. Prevalence is the number of people estimated to 
have a defi ned condition divided by the total number of people studied. Mortality is 
a measure of the number of deaths (all-cause, or due to a specifi c cause) in a particu-
lar population, per unit of time. Incidence, prevalence, and mortality are usually ex-
pressed as fractions, percentages or the number of cases per 10,000 or 100,000 people. 
The prevalence of a chronic disease depends on the incidence of the disease and all-
cause mortality. Temporal trends for prevalence of a chronic disease depend on trends 
for risk factors, incidence, treatment, mortality, and demography (the composition of a 
population). In the ideal epidemiological investigation, a representative cohort, where 
results may be generalized to other populations, is studied. However, there may be se-
lection bias involved in observational research, mainly due to practical reasons, why 
the characteristics of the included cohort are important for interpretation of results. 
The epidemiology of heart failure
HF is a major health problem worldwide with an estimated prevalence of about 1-2% 
in the Western world based on studies of selected cohorts with geographical or age-
realted limitations (2, 89, 90). Studies of prevalence of HF are important due to the 
high mortality (89) and morbidity (91) observed in patients with HF and, in addition, 
because of high economic costs related to HF care (92). Both incidence of HF and 
mortality in HF decreased in the 1990s (93). The prevalence of HF has been reported 
to be higher in older persons when compared to younger persons (89, 90). It has been 
observed that women  have been older when diagnosed with HF, have survived longer 
after onset of HF, and more often have been classifi ed with HFpEF when compared to 
men (94). Warnings of a HF ‘epidemic’ have been expressed (95), not at least due to 
the demographic transition in Western societies.
Swedish registries
Sweden has a long history of registry holding. Swedish church congregations reg-
istered births, marriages and deaths in church books from the beginning of the 17th 
century. Records from the 18th century are almost complete. In parallel there were 
census lengths kept by the Swedish tax agency. The fi rst tax census was performed 
in 1571 and yearly tax registration of citizens that were considered taxable has been 
performed since 1652. From 1946 tax registration was based on church records until 
30 June 1991 when tax and church registries were merged and the responsibility of the 
Swedish Population Registry was transferred to the Swedish Tax Agency. From 1947 
all persons that have resided in Sweden have been assigned an individual personal 
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identity number (PIN) that is used in all offi cial registries (96). Until year 2000, PINs 
were sometimes assigned to individuals who had not been registered in the Swedish 
Population Registry. From 2001, individuals that do not qualify for a PIN receive a 
personal coordination number. 
The Swedish Hospital Discharge Register (also called the Swedish National Inpatient 
Register (IPR)) contains individual data for all inpatient hospital discharges in Swe-
den since 1987. This data include primary diagnosis, up to fi ve secondary diagnoses, 
admission dates, and discharge dates. The IPR has been in operation since the 1960s 
and on a nationwide basis since 1987. From 1984 to 1986, data was available from 19 
of 24 Swedish counties, comprising about 85% of the Swedish population. In recent 
years, more than 99% of hospital stays are registered in IPR, and the overall validity 
of a diagnosis in IPR is 85–95% (97). The validity of an ICD diagnosis of HF in the 
fi rst position in IPR against the ESC criteria for HF is 95%, irrespectively of clinic 
(98). The validity for an ICD diagnosis of HF in any position at an internal medicine 
or cardiology clinic against the ESC criteria for HF is 86% and 91%, respectively. In 
contrast, the validity of a HF diagnosis in Swedish primary health care records against 
the ESC criteria for HF is 30% (99). 
The Swedish Heart Failure Registry (SwedeHF) is a nationwide registry with ap-
proximately 80 variables on aetiology, diagnostic evaluation, treatment and follow-up 
(100). SwedeHF was created as a pilot in 2000 and introduced throughout Sweden 
in 2003. Inclusion criteria are clinician-judged HF. Patients are registered either at 
hospital discharge or in outpatient clinics. Establishment of the registry, and registra-
tion and analysis of the data are approved by a multisite ethics committee. Individual 
patient consent is not required or obtained. 
The Swedish Prescribed Drug Register (SPDR) holds records of all dispensed drugs 
in Sweden since 1999, and since July 2005 with PIN (101). For drug dispensations, 
the registration is complete (although demographic data are missing in 0.02–0.6% of 
cases). 
The Swedish Cause of Death Register (CDR) has been in operation since 1961. Until 
2011, all deceased persons who by the time of death were registered in Sweden, irre-
spectively if death occurred in Sweden or abroad, were included in CDR. From 2012, 
all persons that die in Sweden, irrespectively if they were registered in Sweden or not 
have been included in CDR.
Missing data
There is a risk of missing data in observational databases. Missing data can introduce 
a substantial amount of bias (102). The process of replacing missing data with substi-
tuted values is called imputation. The method of ‘Multiple Imputation’ was developed 
in 1987. The imputed values are drawn m times from a distribution rather than just 
once. At the end of this step, there should be m completed datasets. Each of the m da-
tasets is analysed. At the end of this step there should be m analyses. The m results are 
consolidated into one result by calculating the mean, variance, and confi dence interval 
of the variable of concern. 
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Estimations of survival and risk in observational research
To study the effects of given treatments the golden standard is considered to be RCTs. 
However, there may be limitations with RCTs related to selection bias, ethics, or prac-
tical reasons. In these cases, observational research may be used. Selection bias in 
observational research may infl uence the outcome (103) and associations reported in 
observational research do not prove that there are causal relationships. 
In 1958 the Kaplan–Meier estimation was presented. In medical research, it is often 
used to measure the fraction of patients living for a certain time after treatment. An 
advantage of the Kaplan–Meier curve is that this method can take into account some 
types of censored data, particularly right-censoring, which occurs if a patient with-
draws from a study, is lost to follow-up, or is alive without event occurrence at last 
follow-up. However, the Kaplan-Meier method is limited in its ability to estimate 
survival adjusted for covariates. 
For comparison of observed risks in two different groups, the proportional hazard 
model was proposed in 1972. The proportional hazard model (Cox regression) evalu-
ates the effect of covariates independently of the underlying baseline hazard function 
and reports these effects as a hazard ratio (HR) for a specifi ed outcome, 0 or 1. The 
HR associated with a categorical variable compares the risk in patients with and with-
out the variable and the HR of a continuous variable is the proportional scaling of the 
hazard related to an increase of one unit of the variable. 
However, confounding factors may infl uence the results in risk estimations. A con-
founder is a variable that infl uences both the dependent variable and independent 
variable causing a false association. Different methods how to adjust for confound-
ing factors have been proposed. In a multi-variate Cox regression model, risk after 
adjustment for confounding factors may be estimated. In 1983, another method how 
to adjust for potential selection bias, confounding, and differences between treatment 
groups in observational studies using logistic regression called ‘Propensity Score’ 
was proposed. The propensity score (PS) confers the propensity from 0 to 1 to receive 
a specifi c treatment in a specifi c cohort based on a set of known baseline variables. 
Treated and untreated patients with the closest PS can be matched. A small accepted 
difference in PS between treated and untreated patients in a PS matched cohort in-
crease similarities in baseline variables between treated and untreated patients but to 
the cost of more patients being excluded from the original cohort. The standarized dif-
ference is the difference between the means for treated and untreated patients divided 
by mutual standard deviation. For comparison of descriptive data between the origi-
nal and matched cohorts, standardized differences in both cohorts may be calculated. 
Quantifi cations of the effects of hypothetical unmeasured confounders necessary to 
change the results of an estimation of relative risk may be performed (104). 
Potential confounders in estimations of mortality risk in chronic heart 
failure
Several clinically usable risk models or scores have evaluated risk predictors for long-
time mortality in patients with CHF. Potential confounders in estimations of associa-
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tions between diuretic treatment and long-term mortality in patients with CHF may 
be selected from these models. The Meta-Analysis Global Group in Chronic Heart 
Failure (MAGGIC) score is based on a meta-analysis of individual data on 39,372 
patients with CHF, including both reduced and preserved left-ventricular EF, from 30 
cohort studies, six of which were clinical trials (105). The MAGGIC risk score evalu-
ated 31 different variables for long-term all-cause mortality in HF and identifi ed 13 
independent and two interaction risk predictors. 
Models for prediction of risk
The accuracy of a predictive model may be measured in how well a model separates 
the group being examined into those with and without the specifi ed outcome. The 
area under the receiver operating characteristic (ROC) curve, known as the AUC, is 
currently considered to be the standard method to assess the accuracy of predictive 
models.  Predictive models for specifi c outcomes based on risk scores for patients 
with CHF are available. An area of 1 represents a perfect model; an area of 0.5 and 
below represents that the result is by chance. 
Figure 1. Example of receiver operatin characteristic curve.
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THE RATIONALE OF THE THESIS
Paper I
No study has previously investigated trends in prevalence of patients hospitalized 
with HF in a nationwide cohort. 
Paper II
Temporal trends for diuretic treatment and coinciding neurohormonal antagonist 
treatment rates after a fi rst-time hospitalization for HF have never been studied in a 
nationwide cohort. 
Paper III
The association of diuretic treatment with mortality has previously been studied in 
selected cohorts with HF with limited possibilities to adjust for confounders. Conges-
tion is the main reason for hospitalization for HF (2) Higher mortality rates have been 
observed in patients hospitalized for HF when compared to outpatients with HF (103). 
The association of diuretic treatment at hospital discharge with short- term all-cause 
mortality in unselected real-life patients with HF has never been studied. The associa-
tion of diuretic treatment at hospital discharge with long-term all-cause mortality has 
never been studied in unselected Western world real-life patients with HF.
Paper IV
Diuretic treatment is a strong predictor for long-term mortality in HF scores but has 
not been considered as an additional risk predictor in the HF score with the largest 
underlying database; the MAGGIC score.
23
AIMS
The overall aims of this thesis was: 
I   to estimate trends for prevalence of patients hospitalized with HF in a nation-
wide cohort, by sex and age
II   to estimate trends for diuretic treatment and coinciding neuro-hormonal an-
tagonist treatment rates after a fi rst-time hospitalization for HF in a nation-
wide cohort, by sex and age
III   to estimate the association of diuretic treatment at hospital discharge with all-
cause short- and long-term mortality in unselected real-life patients with HF
IV   to evaluate diuretic treatment as a predictor for long-term all-cause mortality 
in unselected real-life outpatients with HF.
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METHODS
Paper I
All patients hospitalized in Sweden for any reason at least once during 1980-2007 
with a principal or contributory diagnosis of HF and aged between 19 and 99 years 
at any time during the period 1990–2007 were eligible for inclusion in this study. A 
person in this study is considered to have a diagnosis of HF during the period between 
the incident year when he, or she, for the fi rst time was hospitalized with a fi rst or 
contributory diagnosis of HF and the year of death. ICD version 8 (ICD-8) was used 
until 1986, ICD-9 between 1987 and 1996, and ICD-10 from 1997 onwards. The dis-
charge codes applied to HF were 427.00, 427.10 (ICD-8), 428A, 428B, 428X (ICD-
9), and I50 (ICD-10). Data from IPR and CDR was merged. Prevalence of patients 
aged 19-99 with an ICD diagnosis of HF at hospital discharge for each calendar year 
1990-2007 and temporal trends for prevalence in the total cohort, by sex and age were 
estimated. Predefi ned age groups were 19-54, 55-64, 75-84, and 85-99 years. In order 
to estimate the prevalence for a specifi c age X on a specifi c year Y, to the actual in-
cident cases year Y the 1-year survivors among the incident cases of age X-1 at year 
Y-1 and the 2-year survivors among incident cases of age X-2 at year Y-2 are added 
and so on. The counting method was described more formally by Gail (106). Popula-
tion data for the Swedish population for the corresponding age and/or sex-specifi ed 
group and calendar year was used as reference populations in all prevalence estimates. 
This data was provided by the Swedish governmental agency Statistics Sweden. The 
Swedish general population in year 2000 was used as the reference for age-adjusted 
prevalence rates that were computed by using direct standardization. Temporal trends 
were estimated with “Joinpoint regression”. A two-sided P value <0.05 was consid-
ered statistically signifi cant. SAS software version 9.2 (SAS, Cary, NC, USA) and R 
software version 2 (R Development Core Team) were used for data analysis. Join-
point Regression Program 4.0.4 – May 2013 (Statistical Methodology and Applica-
tions Branch, Surveillance Research Program, National Cancer Institute) was used for 
joinpoint analysis. The study was approved by the Regional Ethical Review Board of 
University of Gothenburg.
Paper II
Patients that survived for 18 months or more after a fi rst-time hospitalization for HF 
2005-2014 were eligible for inclusion in this study. We defi ned a hospital admission 
registered 2005-2014 in the IPR with HF as the primary diagnosis with no previous 
admission for HF in the past seven years as a fi rst-time hospitalization for HF. The 
discharge codes applied to HF in this study were I11.0, I13.0, I13.2, I42.0, I42.3-9, 
I50.0-1, and I50.9 (ICD10). The discharge codes applied to comorbidities in this study 
are shown in Table 2.The Anatomical Therapeutic Chemical (ATC) codes used for 
classifi cation of HF treatment investigated in this study are shown in Table 3.  Diuretic 
in combined preparations were thiazides. At least one dispensed prescription of a drug 
class during a specifi ed period was defi ned as treatment with that drug class dur-
ing that period. The Defi ned Daily Dose (DDD) is the assumed average maintenance 
dose per day for a drug used for its main indication in adults and defi ned by WHO 
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Comorbidity ICD10 codes 
Ischaemic heart disease I20-I22, I24, I25 
Valvular disease I34-I37 
Stroke I60-I64, I69 
Periferial arterial disease I70, I73.9 
Chronic obstructive pulmonary disease  J44 
Renal failure  N17.0-N17.2, N17.8-N17.9, N18   
Sleep apnoea syndrome  G47.3 
Diabetes mellitus  E10, E11, E12, E13, E14 
Obesitas  E66.0-E66.2, E66.8-E66.9 
Hypertension I10, I11.9, I12.0-I12.9, I13.1-I13 
Atrial fibrillation I48 
Table 2. ICD codes used for comorbidities at hospital discharge
Table 3. Anatomical Therapeutic Chemical codes for treatment for 
heart failure
Drug class Drug ATC code 
Loop diuretics furosemide  C03CA01   
 bumetanide  C03CA02   
 torasemide  C03CA04   
Digitalis digitoxin  C01AA04   
 digoxin  C01AA05   
MRA spironolactone C03DA01   
 eplerenone C03DA04   
Beta-blockers metoprolol  C07AB02   
 bisoprolol  C07AB07   
 carvedilol  C07AG02   
 atenolol  C07AB03   
 metoprolol and felodipine  C07FB02   
RAS antagonists captopril  C09AA01   
 enalapril  C09AA02   
 lisinopril  C09AA03   
 perindopril C09AA04   
 ramipril C09AA05   
 fosinopril C09AA09   
 enalapril and diuretics C09BA02 
 lisinopril and diuretics C09BA03 
 ramipril and diuretics C09BA05 
 quinapril and diuretics C09BA06 
 losartan C09CA01   
 eprosartan C09CA02   
 valsartan  C09CA03   
 irbesartan C09CA04   
 candesartan  C09CA06   
 telmisartan  C09CA07   
 losartan and diuretics  C09DA01   
 eprosartan and diuretics  C09DA02   
 valsartan and diuretics  C09DA03   
 irbesartan and diuretics  C09DA04   
 candesartan and diuretics C09DA06   
 telmisartan and diuretics  C09DA07   
 valsartan and amlodipine C09DB01   
If channel antagonist ivabradine C01EB17 
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Collaborating Centre for Drug Statistics Methodology (https://www.whocc.no/ddd/
defi nition_and_general_considera/ 170314). The DDD is 40 mg for furosemide, 1 mg 
for bumetanide and 15 mg for torasemide. Registry data from IPR, SPDR and CDR 
was merged. Temporal trends for treatment rates were evaluated with the Cochran-
Armitage test. Temporal trends for DDD were evaluated with linear regression. Sig-
nifi cance level was set at 0.05. SAS software version 9.2 (SAS, Cary, NC, USA) and 
R software version 2 (R Development Core Team) were used for data analysis. The 
study was approved by the Regional Ethical Review Board of Gothenburg University. 
Paper III and IV
Patients registered in SwedeHF 2005-2011 with known diuretic treatment status were 
eligible for inclusion in these studies. Data from SwedeHF and the Swedish Popu-
lation Registry was merged. The cohort was separated into two study populations 
- patients registered at hospital discharge (Paper III) and outpatients (Paper IV). In 
each study population, multiple imputation (n=10) was performed for missing data in 
baseline variables. In Paper III, propensity scores based on 46 baseline variables for 
the propensity between 0 and 1 for each included patient to be treated with diuretics 
were estimated using logistic regression. In Paper IV the corresponding propensity 
scores were based on the 15 MAGGIC risk predictors. We created 1:1 PS matched 
cohorts with accepted maximal differences in PS of 0.01 between a patient treated 
with diuretics and a patient not treated with diuretics. For descriptive analyses original 
data was used. Continuous variables were presented as mean (standard deviation) or 
median (interquartile range) if non-normally distributed. Categorical variables were 
presented as counts and percentages. Comparisons between groups were made us-
ing the chi-square test for categorical variables, the independent samples t-test for 
normally distributed continuous variables, and the Mann–Whitney U test for continu-
ous variables with a skewed distribution. Standardized differences were calculated. 
For survival analyses, multiple imputed data was used. Kaplan-Meier estimates of 
long-time survival in patients with and without diuretics in the original and matched 
cohorts were performed. All-cause mortalities at end of follow-up for patients with or 
without diuretics at baseline were compared with the log rank test in the original and 
matched cohorts, respectively. The unadjusted relative risk of all-cause mortality, the 
relative risk for all-cause mortality adjusted for PS, and the relative risk for all-cause 
mortality in the PS matched cohorts associated with diuretics were estimated. In Paper 
IV, the relative risk for all-cause mortality associated with diuretics adjusted for the 15 
MAGGIC mortality risk predictors was estimated. In Paper IV, time-dependent ROC 
curves (89) for the ability to predict 3-year mortality of the MAGGIC mortality risk 
predictors and the ability to predict 3-year mortality of the MAGGIC mortality risk 
predictors with diuretic treatment as an additional covariate were computed by using 
the patients’ risk scores and areas under the ROC curves were calculated.
A two-sided P value <0.05 was considered statistically signifi cant. Statistical Package 
for the Social Sciences (SPSS; version 22.0, SPSS Inc., Chicago, IL) and R software 
version 2.12.0  (R Development Core Team) were used for data analyses. Establish-
ment of the SwedeHF registry, and registration and analysis of the data were approved 
by a multisite ethics committee.
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RESULTS 
Paper I
Absolute numbers of patients who had been hospitalized with a HF diagnosis and 
were aged 19-99 years increased from 105,449 in 1990 to 144,925 in 2007, with 
a 77% increase in patients aged 85–99 years. The overall prevalence in 1990 was 
1.61% and increased with an estimated annual percentual change (EAPC) of 4.9% 
(95% confi dence interval (CI): 4.4% to 5.4%) from 1990 until 1995, with no further 
signifi cant change until 2001 (Table 4). Prevalence peaked in year 2001 with 2.12% 
and then declined slowly (EAPC: -0.6 (95% CI: −0.9% to −0.2%) to 2.03% in 2007. 
In 1990, the age-adjusted prevalence of patients who had been hospitalized with HF 
in Sweden was 1.70% in men and 1.77% in women. The prevalence in both sexes then 
increased to 2.13% in men and 2.14% in women around 1998–2000. Subsequently, 
the prevalence decreased to 2.03% in men and 1.93% in women. In persons <65 years 
no decrease in prevalence was found, instead, an increase was seen during the obser-
vation period.  
Period 1 Period 2 Period 3 
Years EAPC (95% CI) Years EAPC (95% CI) Years EAPC (95% CI) 
Total population 1990-95 4.3* (3.6 to 4.9) 1995-2002 0.1 (-0.4 to 0.6) 2002-7 -1.1* (-1.5 to –0.6)
Gender        
Men  1990-96 4.4* (3.9 to 4.9) 1996-2007 -0.3* (-0.5 to -0.1)   
Women 1990-96 3.8* (3.4 to 4.3) 1996-2003 -0.4* (-0.8 to -0.1) 2003-7 -1.6* (-2.2 to -1.1) 
Age       
19-54 1990-93 3.6* (2.7 to 4.6) 1993-97 5.7* (5.1 to 6.2) 1997-2007 1.3* (1.2 to 1.4) 
55-64 1990-95 4.9* (4.2 to 5.6) 1995-2004 -0.5* (-0.8 to –0.2) 2004-7 1.3* (0.2 to 2.5) 
65-74 1990-95 6.2* (5.5 to 6.9) 1995-2000 0.4 (-0.2 to 1.1) 2000-7 -1.9* (-2.2 to –1.5)
75-84 1990-95 5.2* (4.6 to 5.8) 1995-2002 0.0 (-0.3 to 0.3) 2002-7 -1.4* (-1.8 to –1.0)
85-99 1990-96 2.4* (1.7 to 3.1) 1996-2004 0.2 (-0.3 to 0.7) 2004-7 -1.3 (-2.9 to 0.4) 
 EAPC, estimated annual percentage change, *significantly different from 0 
Table 4. Joinpoint analysis: trends in prevalence of patients hospitalized with heart failure. Rates 
in the total population, sex-specifi c and age-specifi c.
Paper II
In Paper II 81,531 patients with a fi rst-time hospitalization for HF who survived for 
18 months or longer post-discharge were included (Figure 2). Age, sex and comor-
bidities at hospital discharge are shown in Table 5. Between 2005 and 2014, in the 
period 0-3 months after discharge, loop diuretic drug treatment rates decreased from 
87.2% to 82.3% and median loop diuretic DDD decreased from 2.22 (interquartile 
range 1.11-3.21) to 1.98 (interquartile range 1.11-2.50) (p for trend <0.001 and 0.002, 
respectively), coinciding with a trend for increased treatment with RAS inhibitors and 
beta-blockers during the period (Table 6). Corresponding fi gures for the period 6-18 
months post-discharge were 89.0% and 82.1% and median loop diuretic DDD 1.37 
(interquartile range 1.82-2.19) and 1.10 (interquartile range 0.82-2.05) (p for trends 
<0.001) (Table 7). The median loop diuretic DDD 6-18 months post-discharge was 
lower than the median loop diuretic DDD 0-3 months post-discharge in every calen-
dar year during the study period. Beta-blocker, RAS inhibitor and MRA treatment 
rates  were higher 6-18 months post-discharge than 0-3 months post-discharge (data 
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Figure 2. Flow chart of inclusion of patients.
All patients, n (%) 81,531 (100)
Age and sex 
Age, mean (SD), years 76.0 (12.2)
Sex, n (%) 
  Men 43,665 (53.6)
  Women 37,866 (46.4)
Age group (years), n (%) 
  18-54 4,916 (6.0)
  55-64 8,730 (10.7)
  65-74 16,916 (20.7)
  75-84 29,021 (35.6)
  85-99 21,948 (26.9)
Comorbidities, n (%) 
 Ischaemic heart disease 34,173 (41.9)
 Valvular disease 10,362 (12.7)
 Stroke 11,560 (14.2)
 Periferal arterial disease 5,169 (6.3)
 Chronic obstructive pulmonary disease 8,355 (10.2)
 Renal failure 5,961 (7.3)
 Sleep apnea syndrome 1,916 (2.4)
 Diabetes mellitus 21,222 (26)
 Obesitas 4,063 (5.0)
 Hypertension 47,092 (57.8)
 Atrial fibrillation 40,406 (49.6)
Table 5. Age, sex and comorbidities at hospital dis-
charge
not shown) whereas only small changes, predominantly increases, were observed for 
the coinciding diuretic treatment rates (Table 6). Post-discharge diuretic treatment 
rates were higher in women when compared to men and in older patients when com-
pared to younger patients.
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Paper III and IV
In Paper III 26,218 patients discharged from a hospitalization for HF and registered in 
SwedeHF 2005-2011 (mean age 77.1 + 16.1 years) were included, of whom 87% were 
treated with diuretics and 13% were not treated with diuretics at hospital discharge 
(Figure 3). 
Figure 3. Flow chart of inclusion of patients.
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Baseline characteristics in the original and 1:1 PS matched cohorts are shown in Table 
8. Differences in baseline characteristics were in general smaller in the matched co-
hort when compared to the original cohort.
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Cumulative mortality rates for the original and the 1:1 PS matched cohorts are shown 
in Figure 4. 
Figure 4. Cumulative mortality rates for patients with heart failure treated with 
or without diuretics at hospital discharge in original and 1:1 propensity score 
matched cohorts. 
The unadjusted relative risk of 90-day all-cause mortality associated with diuretics at 
hospital discharge in the original cohort was increased, HR 1.62 (95% CI 1.42–1.85). 
Over a median follow-up of 2.18 years (IQR 0,98-3.91), the unadjusted relative risk 
of long-term all-cause mortality associated with diuretics at hospital discharge was 
increased, HR 1.94 (95% CI 1.82-2.07). After adjustment for PS, the relative risk of 
90-day all-cause mortality associated with diuretics was no longer signifi cantly in-
creased, HR 0.98 (95% CI 0.94–1.02) whereas the long-term all-cause mortality asso-
ciated with diuretics remained moderately increased, HR 1.16 (95% CI 1.14–1.18). In 
the 1:1 PS matched cohort the association of diuretic treatment at hospital discharge 
with 90-day all-cause mortality was neutral, HR 0.89 (95% CI 0.74–1.07). In the 
matched cohort, over a median follow-up of 2.85 years (IQR 1.44-4.42) the relative 
risk of long-term all-cause mortality (median follow-up: 2.85 years) was increased, 
HR 1.15 (95% CI 1.06-1.24). 
In Paper IV 17,518 outpatients (mean age 71.7 years + 12.0 years), 72% treated with 
diuretics, were included (Figure 3). Baseline demographics in the original and 1:1 
propensity score matched cohorts are shown in Table 9. Differences in baseline char-
acteristics were in general smaller in the matched cohort when compared to the origi-
nal cohort.
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Cumulative mortality rates for the original and the 1:1 PS matched cohorts are shown 
in Figure 5.
Figure 5. Cumulative mortality rates for outpatients with heart failure treat-
ed with or without diuretics at baseline in original and 1:1 propensity score 
matched cohorts. 
Over a median follow-up of 2.99 years (IQR 1.74-4.69), the unadjusted relative risk 
for long-term all-cause mortality associated with diuretic treatment was increased, 
HR 2.57 (95% CI 2.51–2.63) and remained signifi cantly increased after adjustment 
for MAGGIC mortality risk predictors in a multi-variate Cox regression model, HR 
1.47 (95% CI 1.43–1.51). After adjustment for PS, the relative risk for long-term all-
cause mortality associated with diuretic treatment in the total cohort was increased, 
HR 1.46 (95% CI 1.42–1.50). In the 1:1 propensity score-matched cohort, over a me-
dian follow-up of 3.46 years (IQR 2.03-5.00) the relative risk for long-term all-cause 
mortality associated with diuretics was increased, HR 1.48 (95% CI 1.35–1.63). For 
prediction of 3-year mortality in our study population a model based on MAGGIC 
mortality risk predictors had an area under the ROC curve (AUC) of 0.78 (0.778). A 
model based on the MAGGIC mortality risk predictors with diuretic treatment as an 
additional covariate had an AUC of 0.78 (0.776).
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DISCUSSION
The prevalence of heart failure
In Paper I, we observed that the prevalence of patients hospitalized with HF in Swe-
den was higher in year 2007 when compared to year 1990 but with a trend for a slight 
decrease in prevalence between 2002 and 2007. Thus, our fi ndings did not support 
that a HF epidemic occurred during the fi nal years of our observation period. How-
ever, the observed increase in the number of patients hospitalized with HF aged >85 
years during our observational period and the coinciding increase in prevalence of 
patients hospitalized with HF in younger ages suggest a possible future increase in the 
overall prevalence of HF. 
The point prevalence of HF has been studied in different cohorts with different meth-
odologies since the 1940s. Data collection for Framingham Heart Study (FHS) began 
in 1948 when 5,209 residents of Framingham, Massachusetts, the United States, aged 
28 to 62 years were enrolled in a prospective epidemiologic study (107). In 1971, 
children of the original study participants and spouses of these children, aged 6 to 70 
years, were entered in the Framingham Offspring Study. In the combined cohort of 
the FHS cohort and the Framingham Offspring Study cohort, the estimated prevalence 
of HF 1948-1988, based on the Framingham diagnostic criteria, was 2.5% in persons 
aged >45 years (89). 
The NHANES-I program included 23,808 non-institutionalized persons 1 to 74 years 
old from the Unites States (90). In the NHANES-I cohort the estimated prevalence of 
HF 1971-1975, based on Framingham diagnostic criteria, was 2% in participants aged 
25-74 years. In Nottinghamshire, United Kingdom, the prevalence of HF 1991-1992, 
based on furosemide prescription data, was estimated to be somewhere between 1.0% 
- 1.6% (108). In the district of Ommoord in Rotterdam, the Netherlands, the estimated 
prevalence of HF 1990-1993, based on assessment of symptoms and signs (shortness 
of breath, ankle oedema and pulmonary crackles) and use of HF medication in 5,540 
invited participants aged 55-95 years in the Rotterdam Study, was 3.9% (109). The 
FHS, NHANES-I, Nottinghamshire and Rotterdam studies reported similar preva-
lence of HF in men and women and higher prevalence of HF in older than in younger 
persons (89, 90, 108, 109). However, estimations in these studies were made on data 
collected before or in the beginning of the modern era of treatment for cardiovascular 
diseases including HF.
Trends for decreased prevalence of cardiovascular risk factors from the 1960s  (110), 
decreased incidence of HF 1988-2000 (93) and decreased mortality in HF 1987-2003 
(111) have been reported in studies based on registry data from Sweden. Other studies 
have reported trends for increased prevalence of HF between 1994 and 2003, based 
on data from medical records of patients 65 years or older covered by Medicare (112), 
and increased prevalence of HF between 2000 and 2005, based on data from medical 
records of medically insured in- and outpatients in the south-eastern United States 
(113). The validity of a diagnosis of HF in the medical records used in the Medicare 
study was not reported. The validity of an ICD-9 diagnosis of HF in the medical re-
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cords used in the study of insured patients against Framingham clinical criteria was 
97% for inpatients but was not reported for outpatients. In both these studies a higher 
prevalence of HF in men than in women was observed (112, 113). 
Between 1987 and 2001, an increased proportion of all patients hospitalized for HF 
were classifi ed with HFpEF and a trend for improved survival in HFrEF but not in 
HFpEF was observed (26). However, observed trends for increased prevalence of HF-
pEF may have been associated with an increased awareness of HFpEF, development 
of new methods how to assess diastolic dysfunction, and an increased tendency to use 
these methods. 
Since the end of the 1990s, the proportion of patients with HF treated with medica-
tions with proven prognostic benefi t in both HFrEF and other cardiovascular diseases 
than HF have increased (82). Between 2000 and 2010, trends for decreased incidence 
of both HFrEF and HFpEF, but more pronounced for HFrEF, was observed (114). A 
coinciding trend for decreased incidence of HF in both men and women, but more 
pronounced for women, and particularly pronounced for HFrEF in women, were ob-
served. In addition, recent studies have suggested that the trend for decreased mor-
tality observed in patients with HF during the 1990s decelerated in the beginning of 
the 21st century (80, 84). No differences were observed in all-cause mortality rates 
between 1998–2002 and 2003–2007 in patients with a fi rst hospitalization for HF (84) 
or in all-cause mortality rates between 2003 and 2012 in patients with chronic HFrEF 
(80). 
These observations suggested a potential difference between trends for prevalence of 
HF before and after the turn of the millennium. Our study on trends for prevalence 
of patients hospitalized with HF between 1990 and 2007 (Paper I) showed two main 
trends; increased prevalence until 1990-1995 and a slight decrease 2002-2007. The 
decreased prevalence of HF in the total cohort coincided with a decrease in women 
but not in men. In consistency with our results, decresed prevalence of HF between 
2006 and 2010 was observed in women, but not in men, in a study based on data from 
the region of Stockholm, Sweden (115). 
No data on EF was available in the registries used in this study (Paper I). A possible 
increase in the proportion of patients with HFrEF and decrease in the proportion of 
patients with HFpEF may have occured in our study cohort during the observation 
period. Beginning around 1995-2000 trends for increased prevalence of HFpEF, de-
creased prevalence of HFrEF, and no signifi cant change in the prevalence of total HF 
(both HFrEF and HFpEF) in older adults have been reported in a recently published 
meta-analysis (116). In addition, it has been reported in European Registry Data that 
both all-cause hospitalizations and hospitalizations for HF may be more common in 
patients with HFrEF when compared to patients with HFmrEF or HFpEF (24). 
The contemporary incidence of HF in Sweden is 3.8/1000 person-years in adults 
(both women and men), 3.2/1000 person-years in women and 3.0/1000 person-years 
in men (115). The contemporary one-year all-cause mortality rate in Europe is 17.4% 
in patients with AHF and 7.2% in patients with CHF  (103) whereas the 5-year mortal-
ity rate n Sweden in adults is approximately 50% (115). 
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The current demographic transition in combination with the increased prevalence ob-
served for many risk factors for HF, e.g. diabetes (Global burden of diabetes, In: 
Diabetic Atlas 5th ed. Brussels: International Diabetes Federation; 2011. Available 
at http://www.idf.org/diabetesatlas (Accessed 30th April 2013), obesity (117), atrial 
fi brillation (118), and a sedentary lifestyle (21) may predispose for a future increase 
in the prevalence of HF.  
Treatment with diuretics in patients with heart failure
In our study (Paper II) a trend for increased post-discharge neuro-hormonal antago-
nist treatment rates coincided with a trend for decreased diuretic treatment rates and 
diuretic doses between 2005 and 2014 in patients with a fi rst-time hospitalization for 
HF. In every calendar year during our observation period, neuro-hormonal antago-
nist treatment rates were higher 6-18 months post-discharge when compared to 0-3 
months post-discharge suggesting that neuro-hormonal antagonist optimization after 
a fi rst-time hospitalization for HF did occur in our cohort. The coinciding changes in 
diuretic treatment rates and diuretic doses suggested that neuro-hormonal antagonist 
optimization after a fi rst-time hospitalization for HF coincided with diuretic dose re-
duction more frequently than with diuretic discontinuation. 
The trends for increased post-discharge neuro-hormonal antagonist treatment rates 
between 2005 and 2014 that were observed in our study are in consistency with re-
sults in previous studies of more selected cohorts with geographical or age-related 
limitations (80-85). In our study, lower treatment rates for RAS inhibitors and beta-
blockers were observed in women when compared to men and in older persons when 
compared to younger persons in consistency with previous fi ndings on treatment pat-
terns in patients with HF (86, 87). Trends for decreased diuretic treatment rates 0-3 
months post-discharge between 2005 and 2014 were observed in our study whereas 
previous studies of more selected cohorts with follow-up until 2010 have reported 
trends for unchanged or relatively constant early post-discharge diuretic treatment 
rates (82, 83). The trends for decreased diuretic treatment rates 6-18 months post-
discharge observed in our study were in consistency with results in previous studies 
of more selected cohorts with CHF and follow-up until 2012 (81, 84, 85). In addition, 
we observed higher diuretic treatment rate in women when compared to men and in 
older persons when compared to younger persons.
Diuretic discontinuation in patients with HF that were considered clinically stable has 
been investigated in some smaller clinical trials (119, 120). In those studies, many pa-
tients needed reintroduction of diuretics. In our study, in every calendar year, loop di-
uretic treatment rates decreased between 0-3 months and 6-18 months post-discharge 
in patients aged <65 years whereas they increased in patients aged >65 years. This 
suggests that the possibilities for successful diuretic discontinuation may differ with 
age. In contrast, diuretic dose decreased between 0-3 months and 6-18 months post-
discharge irrespective of age in every calendar year during our observation period.
However, if there was a direct relationship between improved treatment with neuro-
hormonal antagonists, decreased degree of fl uid retention and decreased need for di-
uretic treatment was not answered by this observational study. We had no data on 
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symptomatic severity. The trend for decreased treatment with diuretics in HF may 
have coincided with a possible trend for less severe HF with a lower degree of conges-
tive symptoms. 
The association of diuretic treatment at hospital discharge with short- 
and long-term mortality in patients with heart failure
The association of diuretic treatment at hospital discharge with short-term mortality 
has never previously been investigated. In our study (Paper III), the association of 
diuretic treatment at hospital discharge with 90-day (short-term) mortality was neu-
tral. In all other settings and lengths of follow-up in patients with HF diuretic treat-
ment has been associated with increased mortality. In theory, a possible mechanistic 
link between diuretics at discharge and short-term mortality may be related to the 
observations that a large proportion of patients have residual clinical or sub-clinical 
congestion at discharge from a hospitalization for HF (10, 70) and that residual con-
gestion at discharge has been associated with increased short-term mortality (10, 70). 
The hypothesis that the relative risk of short-term mortality associated with diuretic 
treatment in HF may differ between patients with congestion when compared to pa-
tients without congestion needs to be verifi ed in a RCT, if possible. The association of 
diuretic treatment at hospital discharge with increased long-term mortality observed 
in our study of a Western world cohort with 26,218 patients (46) was in consistency 
with results from a report from the Japanese HF registry (n=2,549, mean follow-up 
2.1 years) (72). 
In consistency with our results, studies of selected cohorts of patients with CHF have 
reported associations between  diuretic treatment and increased long-term mortality; 
a higher dose of diuretics when compared to a lower dose at baseline has been as-
sociated with increased long-term mortality both in patients with low (121-123) and 
in patients with high beta-blocker treatment rates (124) and non-potassium sparing 
diuretic treatment has been associated with increased long-term mortality in patients 
with chronic HFrEF and low beta-blocker treatment rates (125). Several pathophysi-
ological mechanisms have been proposed to link diuretic treatment mechanistically 
with an increased long-term mortality in CHF, including increased activity of the renin 
angiotensin aldosterone and the sympathetic nervous systems (67, 75), impairment of 
renal function (126, 127) and arrhythmias induced by serum electrolyte disturbance 
(128). Successful withdrawal of diuretics in patients with CHF has been associated 
with decreased PRA and aldosterone levels, unchanged norepinephrine levels and in-
creased natriuretic peptide levels (119, 120). The observed coinciding changes in di-
uretic treatment and changes in levels of neuro-hormones suggest that there may be a 
direct relationship between diuretic treatment and the neuro-hormones that have been 
associated with increased mortality in patients with HF.
The association of diuretic treatment with long-term mortality in outpa-
tients with heart failure
In our study (Paper IV), diuretic treatment was associated with increased long-term 
mortality in a cohort of 17,518 unselected real-life outpatients with HF after adjust-
ment for the 15 MAGGIC mortality predictors. However, an additional covariate 
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would have needed a stronger association with mortality than the one we estimated 
for diuretics in this cohort to improve the ability to predict 3-year mortality of the 
original MAGGIC predictors. 
The observed association of diuretic treatment with increased long-term mortality in 
outpatients with HF was in consistency with results reported in a secondary retrospec-
tive analysis of a selected cohort from the Digitalis Investigation Group (DIG) study 
(79). The secondary DIG analysis included 7,788 outpatients with HF in sinus rhythm 
(median follow-up 40 months). It was based on data collected 1991–1993 and did not 
report the concomitant beta-blocker treatment rate (but it was probably low). Diuretic 
treatment as an independent predictor of long-term mortality has been evaluated in 
CHF risk scores other than MAGGIC, and, in consistency with our results, has been 
shown to be an independent risk predictor. In the Seattle HF mortality risk score, 
based on 1,125 patients with HF with EF<30% and NYHA III-IV from the Prospec-
tive Randomized Amlodipine Survival Evaluation (PRAISE1), diuretic dose was the 
strongest predictor for increased long-term mortality (129) and in the Barcelona HF 
score, based on 864 consecutive outpatients with HF according to ESC criteria treated 
at a single-centre multidisciplinary HF unit, diuretic treatment was a strong predictor 
for increased long term-mortality (130). 
Possible confounders in estimations of the association of diuretic treat-
ment with mortality in patients with heart failure
Diuretic treatment in real-life patients at discharge from a hospitalization for HF or in 
real-life outpatients with HF may be a marker for congestion or HF disease severity 
(131). Congestion and HF disease severity are very complicated to measure (132). 
Out of diuretic treatment, congestion and HF disease severity, diuretic treatment is, 
by far, the easiest variable to measure. Therefore, we consider our fi ndings in Paper 
III and IV of importance even if the prognostic effects of diuretics remain unknown.
If the observed association between diuretic treatment and increased mortality de-
pended on a direct mechanistic link between diuretics and mortality (Paper III and 
IV), the observed temporal trends for decreased diuretic treatment rates and doses 
(Paper II) may have infl uenced the observed temporal trend for decreased prevalence 
of HF (Paper I). However, if diuretic treatment is considered as a marker of HF dis-
ease severity (Paper III and IV), the observed temporal trend for decreased diuretic 
treatment (Paper II) and the observed trend for decreased prevalence of patients hos-
pitalized with HF (Paper I) may have been signs of a temporal trend for decreased HF 
severity. To clarify the prognostic effects of diuretics, RCTs on diuretic treatment and/
or diuretic discontinuation and/or diuretic dose reduction are needed. 
Strengths and limitations
In Paper I all real-life patients hospitalized with a fi rst or contributory diagnosis of 
HF recorded in a nationwide hospital discharge register were included. Thus, patients 
without hospitalizations were not included. In theory, changed indications for hospi-
talizations or changed frequencies of diagnosis setting in medical records may have 
infl uenced our results. In Sweden, the number of secondary diagnoses per case in 
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inpatient care increased during the 1990s after the introduction of diagnosis-related 
group-based prospective payment systems. Most of this increase took place in the 
early 1990s. However, no other major changes in the Swedish hospital or reimburse-
ment systems occurred during our observation period. In addition, the validity of a 
diagnosis of HF in Swedish inpatients has been shown to be higher than in Swedish 
outpatients. No data on EF was available in the registries used in Paper I.
In Paper II all patients that survived 18 months post-discharge after a fi rst-time hospi-
talization for HF 2005-2014 recorded in a nationwide hospital discharge register were 
included. That all patients in this study were included after a fi rst-time hospitaliza-
tion for HF probably limited the impact of a possible HF duration bias. The sickest 
patients who died during the fi rst 18 months post-discharge were not included in this 
study. Nevertheless, 81,531 patients (mean age 76.0 + 12.2 years), of whom 46% 
were women, were included. One limitation in this study was that no data on EF was 
recorded in the registries that were used in Paper II. However, the trends for increased 
treatment with neuro-hormonal antagonists were solid during our observation period 
why it was assumed that no major changes in the distribution of EF occurred. Data on 
the severity of HF was not recorded in the registries used in Paper II. Thus, it remains 
unknown if the temporal trends for decreased loop diuretic treatment rates and doses 
may have been a temporal trend for decreased HF severity. 
In Paper III and IV patients were included form a nationwide HF register, SwedeHF. 
Participation in SwedeHF is voluntary, why there is a risk of selection bias. However, 
SwedeHF has a high coverage rate of hospitals and heart failure outpatient clinics in 
Sweden. We consider our studies on the association of diuretics with mortality the 
most ambitious so far in the number of included patients and in attempts to adjust for 
measured confounders and quantify the possible impact of unmeasured confounders. 
The MAGGIC mortality risk predictors used as co-variates in Paper IV has previously 
been validated to perform very well in predicting survival in the SwedeHF cohort 
(133). In our studies (Paper III and IV) the PS matching process selected the least sick 
patients treated with diuretics from the original cohort to match patients not treated 
with diuretics in the 1:1 PS matched cohort. This may limit extrapolation of our fi nd-
ings to patients with a more severe degree of HF than the patients included in our 
analyses. However, we consider it likely that in real-life clinical practice the clinical 
choice to treat or not treat with diuretics is more probable in patients with a less severe 
HF. 
Information on what kind of diuretic agent that was used and diuretic dose was not 
recorded in SwedeHF before 2011. In data from 2011, 96% of all registered diuretics 
in SwedeHF were loop diuretics. The preferred loop diuretic in Sweden during our 
observation period was furosemide. We had no information on the reason of diuretic 
treatment or on changes in diuretic dose during follow-up. The latest verifi ed EF avail-
able at registration was recorded in SwedeHF. However, there was no information on 
whether the patient had been classifi ed with HFrEF, HFmrEF or HFpEF available in 
the registry. Information on causality of death is not provided in SwedeHF. 
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CONCLUSIONS
The overall aims of this thesis was to study temporal trends for prevalence of patients 
with HF, temporal trends for diuretic treatment in patients with HF and the association 
between diuretic treatment and mortality in patients with HF. The conclusion in Paper 
I was that the prevalence of patients hospitalized with HF increased between 1990 
and 2007 in Sweden but with a slight but statistically signifi cant decreasing trend in 
prevalence since 2001, mainly driven by a decreasing trend in women. The prevalence 
of HF increased gradually in patients <65 years. In absolute numbers, patients with 
HF older than 85 years increased by 77% during the study period. The current demo-
graphic transition in the Western world will most likely lead to increased numbers of 
very old patients with HF and probably result in increased costs for HF care in the 
future. When the temporal trends for prevalence of HF had been estimated (Paper 
I) we proceeded to study the temporal trends of diuretic treatment in patients with 
HF (Paper II). The conclusion of Paper II was that trends for decreased loop diuretic 
treatment rates and doses coincided with increased neuro-hormonal antagonist treat-
ment rates in patients with a fi rst-time hospitalization for HF between 2005 and 2014. 
Furthermore, we observed that post-discharge diuretic dose reduction coincided with 
neuro-hormonal antagonist optimization every calendar year during the observation 
period. 
Thus, in Paper I and II we observed a temporal trend for decreased prevalence of HF 
(Paper I) and a temporal trend for decreased treatment with diuretics in patients with 
HF (Paper II). In Paper II it was also observed that a vast majority of Swedish patients 
were treated with diuretics after discharge from a fi rst time hospitalization for HF dur-
ing the observation period. However, the association of diuretic treatment at discharge 
from a hospitalization for HF and the association of diuretic treatment in outpatients 
with CHF with all-cause mortality in an unselected real-life nationwide cohort were 
not known. For this reason we continued with the studies presented in Paper III and 
IV. The conclusions of Paper III were that there was no signifi cant difference in rela-
tive risk for 90-day all-cause mortality between patients with and without diuretic 
treatment at hospital discharge whereas an association between diuretic treatment at 
hospital discharge and increased long-term mortality was observed. The conclusion 
of Paper IV was that diuretic treatment in outpatients was associated with increased 
relative risk for long-term mortality but that a previously known model for predic-
tion of 3-year mortality was not improved when diuretic treatment was an additional 
covariate. Whether the fi ndings in Paper III and IV were the results of independent 
associations of diuretic treatment with mortality or related to measured or unmea-
sured confounders remains unknown. However, we suggest that diuretic treatment 
may be considered as a risk marker for incresed relative risk of all-cause mortality in 
unselected real-life patients with HF. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ SVENSKA
Hjärtsvikt är en sjukdom där hjärtats pumpförmåga är nedsatt. Den nedsatta pumpför-
mågan vid hjärtsvikt beror på att antingen hjärtmuskelns pumpkraft och/eller förmåga 
till avslappning av något skäl är påverkad. Förekomsten av hjärtsvikt har beräknats till 
c:a 1-2% men har aldrig undersökts i ett helt lands befolkning. Hjärtsvikt är ett allvar-
ligt tillständ med hög sjuklighet och hög dödlighet. Personer med hjärtsvikt drabbas 
ofta av vätskeansamling i kroppen. Vanliga tecken vid vätskeansamling på grund av 
hjärtsvikt är andfåddhet och bensvullnad. För att lindra dessa symptom rekommende-
ras vattendrivande behandling (diuretika). Trots att diuretika av olika slag har använts 
i fl era hundra år och att över 80% av alla patienter med hjärtsvikt behandlas med 
diuretika är det okänt hur denna behandling påverkar dödligheten hos patienter med 
hjärtsvikt. Det övergripande syftet med denna avhandling var att undersöka trender 
i förekomsten av hjärtsvikt 1990-2007, trender i förekomsten av diuretikabehandling 
hos personer med hjärtsvikt 2005-2014 och sambandet mellan diuretikabehandling 
och dödlighet hos personer med hjärtsvikt. För att studera detta samkörde vi uppgifter 
från fl era olika svenska register.
Delarbete I visade att av alla personer som var 19-99 år gamla i Sverige 1990-2007 
var andelen med hjärtsvikt c:a 2%. Av alla personer som var 19-99 år gamla var an-
delen med hjärtsvikt högre 2007 än 1990 men minskade något mellan 2002 och 2007. 
Av alla personer som var yngre än 55 år var andelen med hjärtsvikt låg men ökade 
stadigt mellan 1990 och 2007. Antalet personer med hjärtsvikt som var äldre än 85 
år ökade markant under hela perioden. Troligen kommer dessa trender att leda till en 
framtida ökning av både andelen och antalet personer med hjärtsvikt i Sverige samt 
ökade vårdbehov orsakade av hjärtsvikt.
I riktlinjer om hur man ska behandla hjärtsvikt anges att användningen av diuretika 
vid hjärtsvikt bör vara så låg som möjligt eftersom man inte vet hur diuretika påver-
kar dödligheten vid hjärtsvikt. Delarbete II visade att andelen personer med hjärtsvikt 
som behandlades med diuretika och deras diuretikadoser minskade mellan 2005 och 
2014. Under samma period ökade andelen personer med hjärtsvikt som behandlades 
med andra läkemedel som bevisats minska sjuklighet och dödlighet vid hjärtsvikt. 
Vidare antydde resultaten i delarbete II att bara en liten andel av alla personer som 
hade sjukhusvårdats för första på grund av hjärtsvikt och påbörjat behandling med 
diuretika kunde bli av med denna behandling på sikt. Detta gällde särskilt personer 
med hjärtsvikt som var äldre än 65 år. Däremot verkade dosminskning av diuretika på 
sikt vara vanligt förekommande oavsett ålder.
Delarbete III och IV visade att diuretikabehandling hos personer med hjärtsvikt, både 
vid utskrivning från sjukhus och i öppenvården, hade ett samband med ökad dödlighet 
på lång sikt. Däremot visade sig diuretikabehandling vid utskrivning från sjukhus inte 
ha något samband med förändrad dödlighet på kort sikt. Dessa samband gällde även 
efter att hänsyn tagits till en mängd andra faktorer som kan påverka prognosen hos 
personer med hjärtsvikt. Om det fi nns något direkt orsakssamband mellan diuretika 
och dödlighet hos personer med hjärtsvikt är fortfarande okänt.
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